Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis.
about
Pre- and Post-Transplant Antiviral Therapy (HBV, HCV)Chronic Cholestatic Liver Injury Attributable to Vedolizumab.Systematic review: interferon-free regimens for patients with HCV-related Child C cirrhosis.Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry.Sustained Virological Response after 8-Week Treatment of Simeprevir with Peginterferon α-2a plus Ribavirin in a Japanese Female with Hepatitis C Virus Genotype 1b and IL28B Minor Genotype.Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C-Infected Patients With Compensated and Decompensated CirrhosisSimeprevir and Sofosbuvir Combination Treatment in a Patient with HCV Cirrhosis and HbS Beta 0-Thalassemia: Efficacy and Safety despite Baseline Hyperbilirubinemia.Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection.Direct-acting antiviral drugs for the treatment of chronic hepatitis C virus infection: Interferon free is now.Advances in hepatitis C therapies.Drug-Induced Liver Injury: Highlights from a Review of the 2015 Literature.Prevention and management of treatment failure to new oral hepatitis C drugs.New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs).Special populations: treating hepatitis C in patients with decompensated cirrhosis and/or advanced renal impairment.Highlights of drug - and herb- induced liver injury in the literature from 2016: how best to translate new information into clinical practice?Hepatitis C direct antiviral drugs and hepatic decompensation in patients with advanced cirrhosis: culprit or innocent bystander?Do directly acting antiviral agents for HCV increase the risk of hepatic decompensation and decline in renal function? Results from ERCHIVES.Safety and efficacy of simeprevir plus sofosbuvir with or without ribavirin in patients with decompensated genotype 1 hepatitis C cirrhosis.New hepatitis C therapies for special patient populations.Probable case of drug reaction with eosinophilia and systemic symptom syndrome due to combination therapy with daclatasvir and asunaprevirTreatment of chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and/or ribavirin.Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients.Increased risk of venous thromboembolism in hospitalized patients with cirrhosis due to non-alcoholic steatohepatitis.
P2860
Q26740319-910AB37E-A2E9-4630-8FB4-25718C8BFFC0Q30275619-ADBF165E-5072-4E97-AB9C-18E283C4769AQ30399476-6F38BCC8-3404-4893-8CEA-F0295A707973Q31160142-31D50F12-CEED-47C6-872D-1CBD2AFFF9E5Q35903139-278F91B0-2FE2-4CCF-8E01-CA7A9129429AQ35995534-E4B82569-552F-432A-AC40-1105807D7B59Q36690603-EC996C03-9ECB-4776-BE5A-F0C172C289A9Q38453795-F78F1BB6-0260-436F-8BDC-71E2ED58B07BQ38548066-097CE81E-15A7-4F24-BC72-CD9A9FD7ECC2Q38556401-45C3EFA7-CCAE-43C4-BB63-06D11A8FC91AQ38824550-194528D1-CE49-4D14-A3AE-83988893FCADQ38826624-F0ADA970-A4B8-4C54-8960-C31D47028D56Q39016874-43BDEF97-C665-4C04-8283-8F19A7B6AB92Q39067369-94C9C288-9CFA-4B12-A3CC-2EBB0AEB8B4EQ40096207-0F711747-11EB-4E23-8A09-498C0A1E1BA9Q40364506-A07A8A6C-E097-479D-A22F-FC8C2732250FQ40489570-06185EC9-7B46-4E94-99F0-D4863D281C34Q40579236-62423E9E-BA34-409B-B9EA-A42013F822DDQ40899794-3CFFC628-FC91-4A1C-880D-BE92ED5CBDA3Q41042403-6FBA2AED-8B9E-49C4-BE7A-C039625AF3D9Q41087896-0188AD17-619B-4904-A85F-1A5299F0AAEDQ47593983-4F1F88D7-3995-4F3C-83EC-2F314AD9D8D8Q55342502-B353C0E7-0001-4E2B-88C8-A29B09C65743
P2860
Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis.
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Hepatic decompensation likely ...... ients with advanced cirrhosis.
@ast
Hepatic decompensation likely ...... ients with advanced cirrhosis.
@en
type
label
Hepatic decompensation likely ...... ients with advanced cirrhosis.
@ast
Hepatic decompensation likely ...... ients with advanced cirrhosis.
@en
prefLabel
Hepatic decompensation likely ...... ients with advanced cirrhosis.
@ast
Hepatic decompensation likely ...... ients with advanced cirrhosis.
@en
P2093
P2860
P1476
Hepatic decompensation likely ...... tients with advanced cirrhosis
@en
P2093
Curtis K Argo
James H Lewis
Neeral L Shah
Patrick G Northup
Stephen H Caldwell
P2860
P2888
P304
P356
10.1007/S10620-014-3422-X
P577
2014-11-06T00:00:00Z
P6179
1001343923